Catalent Pharma Solutions received notice that the FDA has approved the sale of a prescription product manufactured at its recently opened pre-filled syringe facility in Brussels, Belgium. Syringes from the Brussels facility will likely be dispensed to patients in the U.S. during the next few months.     Richard Yarwood, group president of Catalent’s Sterile Technologies segment, said, “We are very pleased to have reached this important milestone in the evolution of our Brussels facility, and...